<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.008</object-id><label>Table 2.</label><caption><title>Demographic, clinical and genetic features of the UTUC cohort stratified by UroSEEK results.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th>N</th><th>%</th><th>Ten-gene multiplex positive</th><th>TERT positive</th><th>Aneuploidy positive</th><th>UroSEEK positive</th></tr></thead><tbody><tr><td><bold>All subjects</bold></td><td>56</td><td>100%</td><td>64%</td><td>29%</td><td>39%</td><td>75%</td></tr><tr><td valign="bottom"><bold>Gender</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;Males</td><td>24</td><td>43%</td><td>71%</td><td>33%</td><td>54%</td><td>83%</td></tr><tr><td valign="bottom">&#8195;Females</td><td>32</td><td>57%</td><td>59%</td><td>25%</td><td>28%</td><td>69%</td></tr><tr><td valign="bottom"><bold>CKD stage</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;0&#8211;2</td><td>25</td><td>45%</td><td>68%</td><td>36%</td><td>44%</td><td>76%</td></tr><tr><td valign="bottom">&#8195;3A</td><td>14</td><td>25%</td><td>50%</td><td>21%</td><td>43%</td><td>71%</td></tr><tr><td valign="bottom">&#8195;3B</td><td>10</td><td>18%</td><td>80%</td><td>20%</td><td>40%</td><td>80%</td></tr><tr><td valign="bottom">&#8195;4</td><td>4</td><td>7%</td><td>25%</td><td>50%</td><td>0%</td><td>50%</td></tr><tr><td valign="bottom">&#8195;5</td><td>3</td><td>5%</td><td>100%</td><td>0%</td><td>33%</td><td>100%</td></tr><tr><td valign="bottom"><bold>Tumor grade</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;Low</td><td valign="bottom">6</td><td valign="bottom">11%</td><td>67%</td><td>50%</td><td>17%</td><td>67%</td></tr><tr><td valign="bottom">&#8195;High</td><td valign="bottom">50</td><td valign="bottom">89%</td><td>64%</td><td>26%</td><td>42%</td><td>76%</td></tr><tr><td valign="bottom"><bold>Tumor stage</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;Ta</td><td valign="bottom">11</td><td valign="bottom">20%</td><td>73%</td><td>55%</td><td>45%</td><td>82%</td></tr><tr><td valign="bottom">&#8195;T1</td><td valign="bottom">8</td><td valign="bottom">14%</td><td>50%</td><td>0%</td><td>38%</td><td>75%</td></tr><tr><td valign="bottom">&#8195;T2</td><td valign="bottom">10</td><td valign="bottom">18%</td><td>80%</td><td>20%</td><td>10%</td><td>80%</td></tr><tr><td valign="bottom">&#8195;T3</td><td valign="bottom">24</td><td valign="bottom">43%</td><td>67%</td><td>33%</td><td>54%</td><td>79%</td></tr><tr><td valign="bottom">&#8195;T4</td><td valign="bottom">3</td><td valign="bottom">5%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td valign="bottom"><bold>Upper urinary tract tumor site</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;Lower ureter</td><td valign="bottom">17</td><td valign="bottom">30%</td><td>76%</td><td>18%</td><td>35%</td><td>76%</td></tr><tr><td valign="bottom">&#8195;Upper ureter</td><td valign="bottom">1</td><td valign="bottom">2%</td><td>100%</td><td>0%</td><td>0%</td><td>100%</td></tr><tr><td valign="bottom">&#8195;Ureterovesical junction</td><td valign="bottom">2</td><td valign="bottom">4%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td valign="bottom">&#8195;Lower ureter and upper ureter</td><td valign="bottom">2</td><td valign="bottom">4%</td><td>100%</td><td>50%</td><td>50%</td><td>100%</td></tr><tr><td valign="bottom">&#8195;Renal pelvis</td><td valign="bottom">21</td><td valign="bottom">38%</td><td>57%</td><td>38%</td><td>38%</td><td>76%</td></tr><tr><td valign="bottom">&#8195;Renal pelvis and lower ureter</td><td valign="bottom">4</td><td valign="bottom">7%</td><td>75%</td><td>25%</td><td>50%</td><td>100%</td></tr><tr><td valign="bottom">&#8195;Renal pelvis and upper ureter</td><td valign="bottom">5</td><td valign="bottom">9%</td><td>40%</td><td>40%</td><td>60%</td><td>60%</td></tr><tr><td valign="bottom">&#8195;Renal pelvis, lower ureter, upper ureter</td><td valign="bottom">4</td><td valign="bottom">7%</td><td>75%</td><td>25%</td><td>50%</td><td>75%</td></tr><tr><td valign="bottom"><bold>Synchronous bladder cancer</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;Present</td><td valign="bottom">21</td><td valign="bottom">38%</td><td>52%</td><td>29%</td><td>33%</td><td>62%</td></tr><tr><td valign="bottom">&#8195;Absent</td><td>35</td><td>63%</td><td>71%</td><td>29%</td><td>43%</td><td>83%</td></tr><tr><td valign="bottom"><bold>UTUC risk factors</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom">&#8195;Aristolactam-DNA adducts present</td><td valign="bottom">54</td><td valign="bottom">96%</td><td>65%</td><td>30%</td><td>39%</td><td>74%</td></tr><tr><td valign="bottom">&#8195;Smoking history</td><td valign="bottom">10</td><td valign="bottom">18%</td><td>70%</td><td>30%</td><td>60%</td><td>70%</td></tr><tr><td valign="bottom">&#8195;CKD, chronic kidney disease.</td><td valign="bottom"/><td valign="bottom"/><td/><td/><td/><td/></tr></tbody></table></table-wrap>